[go: up one dir, main page]

WO2024243381A2 - Système de traitement d'un patient - Google Patents

Système de traitement d'un patient Download PDF

Info

Publication number
WO2024243381A2
WO2024243381A2 PCT/US2024/030709 US2024030709W WO2024243381A2 WO 2024243381 A2 WO2024243381 A2 WO 2024243381A2 US 2024030709 W US2024030709 W US 2024030709W WO 2024243381 A2 WO2024243381 A2 WO 2024243381A2
Authority
WO
WIPO (PCT)
Prior art keywords
scaffold
hollow structure
agent
implant location
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/030709
Other languages
English (en)
Other versions
WO2024243381A3 (fr
Inventor
Joseph Rodgers STEELE, Jr.
J. Christopher Flaherty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Steele Physician Services Plcc
Original Assignee
Steele Physician Services Plcc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steele Physician Services Plcc filed Critical Steele Physician Services Plcc
Publication of WO2024243381A2 publication Critical patent/WO2024243381A2/fr
Publication of WO2024243381A3 publication Critical patent/WO2024243381A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A61B17/12113—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2475—Venous valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/1214—Coils or wires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00004—(bio)absorbable, (bio)resorbable or resorptive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00017—Electrical control of surgical instruments
    • A61B2017/00022—Sensing or detecting at the treatment site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • A61B2017/00646—Type of implements
    • A61B2017/00659—Type of implements located only on one side of the opening
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00831—Material properties
    • A61B2017/00893—Material properties pharmaceutically effective
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
    • A61F2250/0031—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time made from both resorbable and non-resorbable prosthetic parts, e.g. adjacent parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0059—Additional features; Implant or prostheses properties not otherwise provided for temporary
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Definitions

  • the scaffold comprises a weave construction.
  • the scaffold comprises a lattice construction.
  • the scaffold comprises a circular cross section.
  • the scaffold comprises a non-circular cross section.
  • the scaffold comprises a varying diameter along its length.
  • the scaffold is configured to be delivered to an implant location that is proximate a damaged area of the hollow structure.
  • the damaged area can comprise an area of perforated tissue.
  • the perforated tissue can comprise perforated tissue of a bowel.
  • the system can be configured to prevent further injury and/or to promote healing.
  • the system can be configured to promote healing via ingrowth of tissue adjacent the implant location.
  • the scaffold further comprises an agent that is configured to be delivered over time.
  • the scaffold can further comprise a coating that surrounds the agent, and the coating can be configured to bioabsorb over time, and the delivery of the agent can be configured to begin after the coating is effectively bioabsorbed.
  • the agent can comprise two or more different agents.
  • the agent can be impregnated within the scaffold.
  • the agent can comprise a coating on a surface the scaffold.
  • the scaffold can be configured to bioabsorb within a first time period, and the agent can be configured to be fully delivered within the first time period.
  • the agent can comprise a pharmaceutical drug.
  • the agent can comprise a pharmaceutical drug selected from the group consisting of chemotherapeutic; anti-coagulant; anti-infective; anti-fungal; anti-inflammatory; an agent configured to decrease cellular activity; an agent configured to increase cellular activity; and combinations thereof.
  • the agent can comprise a radioactive agent.
  • the agent can comprise a genetic therapy agent.
  • the agent can comprise a small molecule agent.
  • the agent can be configured to enhance healing.
  • the agent can be configured to reduce stenosis.
  • the agent can be configured to inhibit tissue growth.
  • the agent can be configured to provide a focal tumor treatment.
  • the delivery device comprises a percutaneous delivery device.
  • the percutaneous delivery device can comprise a catheter.
  • the delivery device comprises a surgical delivery device and/or a laparoscopic delivery device.
  • the delivery device comprises an endoscope.
  • the delivery device comprises an expandable element configured to expand and/or dilate the scaffold.
  • the system further comprises a dilation assembly configured to dilate the hollow structure and/or the scaffold prior to, during, and/or after the delivery of the scaffold to the implant location.
  • the delivery device can comprise the dilation assembly.
  • the dilation assembly can comprise a balloon catheter.
  • the dilation assembly can comprise a device including a radially expandable element, and the radially expandable element can be configured to expand to dilate the hollow structure and/or scaffold.
  • the radially expandable element can comprise a structure selected from the group consisting of mesh net; mallicot; expandable cage; unfurlable element; and combinations thereof.
  • the dilation assembly can be configured to perform a low-pressure dilation.
  • the dilation assembly can comprise an energy delivery element.
  • the dilation assembly can comprise a cutting element, a sonic disruption element, and/or a lithotripsy element.
  • the system further comprises a scoring device configured to score the hollow structure prior to, during, and/or after the delivery of the scaffold to the implant location.
  • the scoring device can comprise a device selected from the group consisting of: scoring sheath; cutting sheath; cutting balloon; and combinations thereof.
  • the scoring device can be configured to treat the hollow structure if the hollow structure comprises a lumen with a stenosis of at least 7mm, and/or if the hollow structure comprises a stenosis of at least 50% (e.g., when compared to normal vessel or viscus).
  • the system further comprises a lumen altering device configured to increase and/or decrease the cross-sectional area of a lumen of the hollow structure.
  • the hollow structure can be a hollow body organ.
  • the lumen altering device can comprise a surgical device and/or laparoscopic device.
  • the lumen altering device can comprise a dilation device.
  • the dilation device can comprise a balloon catheter device.
  • the system further comprises a lithotripsy device configured to disrupt and/or destroy tissue and/or other material within the hollow structure.
  • the lithotripsy device can be configured to perform the disruption and/or destruction of tissue prior to the delivery of the scaffold.
  • the system further comprises a space occluding device configured to reduce space within at least one portion of the hollow structure.
  • the hollow structure can comprise an aneurysm.
  • the space occluding device can be configured to deliver an occlusive agent and/or an occlusive coil.
  • the space occluding device can be configured to modify the flow of fluid through the hollow structure. The modification of flow can comprise a reduction in flow.
  • the hollow structure can comprise a TIPS shunt.
  • the hollow structure can comprise an arteriovenous fistula, and the space occluding device can be configured to stop flow through the arteriovenous fistula.
  • the hollow structure can comprise a portion of the GI tract, and the space occluding device can be configured to reduce flow through the portion of the GI tract to treat dumping syndrome.
  • the space occluding device can comprise one or more space occluding elements that can be configured to bioabsorb over a time period.
  • the space occluding device can be configured to modify flow through the hollow structure for a limited period of time.
  • the one or more space occluding elements can be configured to be effectively bioabsorbed within a time period of no more than: 1 hour; 8 hours; 1 day; 1 week; 1 month; 3 months; 6 months; and/or 1 year.
  • the one or more space occluding elements can be configured to remain effectively in place for a time period of at least: 1 hour; 8 hours; 1 day; 1 week; 1 month; 3 months; 6 months; and/or 1 year, after which the scaffold is configured to be effectively bioabsorbed.
  • the system further comprises a controller and a memory storage component coupled to the controller, and the memory storage component is configured to store instructions for the controller to perform an algorithm, and the algorithm is configured to determine a value for a target procedural parameter.
  • the algorithm can comprise an Al algorithm.
  • the system further comprises a console.
  • the console can comprise a controller including a memory storage component configured to store instructions for the controller to perform an algorithm.
  • the system further comprises one, two, or more functional elements.
  • the one, two, or more functional elements can comprise one, two, or more sensors and/or one, two, or more transducers.
  • the system further comprises a lumen altering device configured to treat the hollow structure in a first treatment, and the scaffold is implanted in the hollow structure in a second treatment, subsequent to the first treatment.
  • the lumen altering device can comprise a device selected from the group consisting of an angioplasty balloon; a cutting balloon; a cryoplasty balloon; an atherectomy device; a device configured to treat a vascular calcification; a lithotripsy device; and combinations thereof.
  • the lumen altering device can be configured to perform a procedure selected from the group consisting of balloon angioplasty; balloon angioplasty in which the balloon is inflated beyond a nominal pressure, such as when inflated to at least 110% of nominal pressure; balloon angioplasty that is performed multiple times at a single anatomical location; balloon angioplasty in which the balloon is maintained expanded for a period of at least 5 minutes; atherectomy including multiple passes of the atherectomy element through the same anatomical location; and combinations thereof.
  • the scaffold is implanted only if the outcome of the first treatment is below a desired result, such as a desired result of residual stenosis being less than 30%.
  • the system comprises a sensor, such as an implantable sensor.
  • the sensor can be configured to produce a signal, and the system can be configured to produce data based on the sensor signal.
  • the system can be configured to analyze the data to determine a system parameter (e.g., a scaffold parameter and/or a treatment parameter).
  • the scaffold can comprise the sensor.
  • a method of treating a hollow structure of a patient comprises: selecting a patient for treatment; and delivering a scaffold at an implant location in the hollow structure of the patient using the system as described herein.
  • the scaffold is configured to bioabsorb over a time period.
  • Fig. 1 illustrates a schematic view of a medical system comprising an implantable scaffold and other components, consistent with the present inventive concepts.
  • Fig. 1A illustrates a flow chart of a method of performing a medical procedure, consistent with the present inventive concepts.
  • operably attached As used herein, the terms “operably attached”, “operably connected”, “operatively coupled” and similar terms related to attachment of components shall refer to attachment of two or more components that results in one, two, or more of: electrical attachment; fluid attachment; magnetic attachment; mechanical attachment; optical attachment; sonic attachment; and/or other operable attachment arrangements.
  • the operable attachment of two or more components can facilitate the transmission between the two or more components of: power; signals; electrical energy; fluids or other flowable materials; magnetism; mechanical linkages; light; sound such as ultrasound; and/or other materials and/or components.
  • first element when referred to as being “in”, “on” and/or “within” a second element, the first element can be positioned: within an internal space of the second element, within a portion of the second element (e.g., within a wall of the second element); positioned on an external and/or internal surface of the second element; and combinations of one or more of these.
  • proximate when used to describe proximity of a first component or location to a second component or location, is to be taken to include one or more locations near to the second component or location, as well as locations in, on and/or within the second component or location.
  • a component positioned proximate an anatomical site shall include components positioned near to the anatomical site, as well as components positioned in, on and/or within the anatomical site.
  • Spatially relative terms such as “beneath,” “below,” “lower,” “above,” “upper” and the like may be used to describe an element and/or feature’s relationship to another element(s) and/or feature(s) as, for example, illustrated in the figures. It will be further understood that the spatially relative terms are intended to encompass different orientations of the device in use and/or operation in addition to the orientation depicted in the figures.
  • a component, process, and/or other item selected from the group consisting of: A; B; C; and combinations thereof shall include a set of one or more components that comprise: one, two, three or more of item A; one, two, three or more of item B; and/or one, two, three, or more of item C.
  • “and” can mean “or”, and “or” can mean “and”.
  • the feature can have A, B, and C, or any combination of A, B, and C.
  • the feature can have only one or two of A, B, or C.
  • a quantifiable parameter when described as having a value “between” a first value X and a second value Y, it shall include the parameter having a value of at least X, no more than Y, and/or at least X and no more than Y.
  • a length of between 1 and 10 shall include a length of at least 1 (including values greater than 10), a length of less than 10 (including values less than 1), and/or values greater than 1 and less than 10.
  • the expression “configured (or set) to” used in the present disclosure may be used interchangeably with, for example, the expressions “suitable for”, “having the capacity to”, “designed to”, “adapted to”, “made to” and “capable of’ according to a situation.
  • the expression “configured (or set) to” does not mean only “specifically designed to” in hardware.
  • the expression “a device configured to” may mean that the device “can” operate together with another device or component.
  • threshold refers to a maximum level, a minimum level, and/or range of values correlating to a desired or undesired state.
  • a system parameter is maintained above a minimum threshold, below a maximum threshold, within a threshold range of values, and/or outside a threshold range of values, such as to cause a desired effect (e.g., efficacious therapy) and/or to prevent or otherwise reduce (hereinafter “prevent”) an undesired event (e.g., a device and/or clinical adverse event).
  • a system parameter is maintained above a first threshold (e.g., above a first temperature threshold to cause a desired therapeutic effect to tissue) and below a second threshold (e.g., below a second temperature threshold to prevent undesired tissue damage).
  • a threshold value is determined to include a safety margin, such as to account for patient variability, system variability, tolerances, and the like.
  • “exceeding a threshold” relates to a parameter going above a maximum threshold, below a minimum threshold, within a range of threshold values and/or outside of a range of threshold values.
  • room pressure shall mean pressure of the environment surrounding the systems and devices of the present inventive concepts.
  • Positive pressure includes pressure above room pressure or simply a pressure that is greater than another pressure, such as a positive differential pressure across a fluid pathway component such as a valve.
  • Negative pressure includes pressure below room pressure or a pressure that is less than another pressure, such as a negative differential pressure across a fluid component pathway such as a valve.
  • Negative pressure can include a vacuum but does not imply a pressure below a vacuum.
  • vacuum can be used to refer to a full or partial vacuum, or any negative pressure as described hereabove.
  • diameter where used herein to describe a non-circular geometry is to be taken as the diameter of a hypothetical circle approximating the geometry being described.
  • the term “diameter” shall be taken to represent the diameter of a hypothetical circle with the same cross sectional area as the cross section of the component being described.
  • major axis and “minor axis” of a component where used herein are the length and diameter, respectively, of the smallest volume hypothetical cylinder which can completely surround the component.
  • a functional element is to be taken to include one or more elements constructed and arranged to perform a function.
  • a functional element can comprise a sensor, a transducer, or both.
  • a functional element is configured to deliver energy, deliver a therapeutic treatment, and/or otherwise perform a function.
  • a functional element e.g., a functional element comprising a sensor
  • a sensor or other functional element is configured to perform a diagnostic function (e.g., to gather data used to perform a diagnosis).
  • a functional element is configured to perform a therapeutic function (e.g., to deliver therapeutic energy and/or a therapeutic agent).
  • a functional element comprises one or more elements constructed and arranged to perform a function selected from the group consisting of: deliver energy; extract energy (e.g., to cool a component); deliver a drug or other agent; manipulate a system component or patient tissue; record or otherwise sense a parameter such as a patient physiologic parameter or a system parameter; and combinations of one or more of these.
  • a functional element can comprise a fluid and/or a fluid delivery system.
  • a functional element can comprise a reservoir, such as an expandable balloon or other fluid-maintaining reservoir.
  • a “functional assembly” can comprise an assembly constructed and arranged to perform a function, such as a diagnostic and/or therapeutic function.
  • a functional assembly can comprise an expandable assembly.
  • a functional assembly can comprise one or more functional elements.
  • transducer where used herein is to be taken to include any component or combination of components that receives energy or any input, and produces an output.
  • a transducer can include an electrode that receives electrical energy, and distributes the electrical energy to tissue (e.g., based on the size of the electrode).
  • a transducer converts an electrical signal into any output, such as: light (e.g., a transducer comprising a light emitting diode or light bulb), sound (e.g., a transducer comprising a piezo crystal configured to deliver ultrasound energy); pressure (e.g., an applied pressure or force); heat energy; cryogenic energy; chemical energy; mechanical energy (e.g., a transducer comprising a motor or a solenoid); magnetic energy; and/or a different electrical signal (e.g., different than the input signal to the transducer).
  • a transducer can convert a physical quantity (e.g., variations in a physical quantity) into an electrical signal.
  • a transducer can include any component that delivers energy and/or an agent to tissue, such as a transducer configured to deliver one or more of: electrical energy to tissue (e.g., a transducer comprising one or more electrodes); light energy to tissue (e.g., a transducer comprising a laser, light emitting diode and/or optical component such as a lens or prism); mechanical energy to tissue (e.g., a transducer comprising a tissue manipulating element); sound energy to tissue (e.g., a transducer comprising a piezo crystal); chemical energy; electromagnetic energy; magnetic energy; and combinations of one or more of these.
  • the term “fluid” can refer to a liquid, gas, gel, or any flowable material, such as a material which can be propelled through a lumen and/or opening.
  • the term “material” can refer to a single material, or a combination of two, three, four, or more materials.
  • the systems of the present inventive concepts comprise a scaffold for implanting in a blood vessel, tubular tissue segment, and/or other hollow structure of a mammalian patient.
  • a human or other mammalian patient is selected for treatment, and a medical procedure is performed in which a scaffold is implanted in a hollow structure of the patient.
  • System 10 comprises scaffold 100, a device for implanting in a hollow structure HS of the patient.
  • System 10 can comprise delivery device 200, a device configured to deliver scaffold 100 to an implant location, location ILOC, within hollow structure HS.
  • Scaffold 100 can be configured to bioabsorb, biodegrade, and/or otherwise decompose after implantation in a patient (any one or more, “bioabsorb” herein).
  • the bioabsorption can occur over a period of time, such as a predetermined time period.
  • the entire scaffold 100 is configured to be effectively bioabsorbed (“bioabsorbed” or “effectively bioabsorbed”), such that no significant portion of the scaffold 100 remains in its original form, and/or is providing its original function (e.g., no longer providing a scaffolding force to tissue).
  • Scaffold 100, and/or one or more portions of scaffold 100 can be configured to be effectively bioabsorbed within a time period of no more than: 1 hour, 8 hours, 1 day, 1 week, 1 month, 3 months, 6 months, and/or 1 year.
  • scaffold 100, and/or one or more portions of scaffold 100 can be configured to remain effectively in place for a time period of at least: 1 hour, 8 hours, 1 day, 1 week, 1 month, 3 months, 6 months, and/or 1 year, after which the scaffold can be configured to be effectively bioabsorbed.
  • scaffold 100 comprises a first portion that is configured to bioabsorb over time, and a second portion that is configured to not bioabsorb.
  • scaffold 100 comprises a first portion that is configured to bioabsorb over time at a first bioabsorption rate, and a second portion that is configured to bioabsorb at a second bioabsorption rate, and the second bioabsorption rate is greater than the first bioabsorption rate.
  • Scaffold 100 can comprise one or more coatings, coating 110 shown.
  • Coating 110 can be configured to bioabsorb over a time period.
  • Scaffold 100 can comprise one or more agents, agent 150 shown.
  • coating 110 comprises agent 150.
  • agent 150 comprises at least two agents, such as agents 150a and 150b as shown.
  • scaffold 100 further comprises an agent 150 that is configured to be delivered over time.
  • Scaffold 100 can further comprise a coating 110 that surrounds agent 150, and coating 110 can be configured to bioabsorb over time, such that delivery of agent 150 can be configured to begin after coating 110 is effectively bioabsorbed.
  • Agent 150 can comprise two or more different agents (e.g., agents 150a and 150b shown). Agent 150 can be impregnated within scaffold 100.
  • Agent 150 can comprise a coating on a surface of scaffold 100 (e.g., coating 110).
  • Scaffold 100 can be configured to bioabsorb within a first time period, and an included agent 150 can be configured to be fully delivered within the first time period.
  • Agent 150 can comprise a pharmaceutical drug, such as a pharmaceutical drug selected from the group consisting of: chemotherapeutic; anti -coagulant; anti-infective; anti-fungal; anti-inflammatory; an agent configured to decrease cellular activity; an agent configured to increase cellular activity; and combinations thereof.
  • Agent 150 can comprise a radioactive agent.
  • Agent 150 can comprise a genetic therapy agent.
  • Agent 150 can comprise a small molecule agent.
  • Agent 150 can be configured to enhance healing, reduce stenosis, and/or inhibit tissue growth.
  • the agent can be configured to provide a focal treatment, such as a focal tumor treatment.
  • Agent 150 can be configured to be delivered in a “bolus” arrangement (absorbs to a point at which the agent is released), or over time (e.g., a slow release).
  • Agent 150 can be configured for local delivery (e.g., to tissue surrounding scaffold 100), and/or it can be configured to migrate (e.g., migrate downstream from scaffold 100).
  • scaffold 100 is configured to cause a desired response within hollow structure HS.
  • the desired response can comprise a remodeling of hollow structure HS.
  • the desired response can comprise a reendothelialization of a wall portion of hollow structure HS.
  • scaffold 100 comprises one or more natural materials, one or more synthetic materials, or at least one natural material and at least one synthetic material.
  • At least a portion of scaffold 100 is configured to be removed after delivery of scaffold 100 to implant location ILOC.
  • the entire scaffold 100 can be configured to be removed after delivery of the scaffold to the implant location.
  • Scaffold 100 can be configured to be removed within 1 day, 1 week, and/or 1 month of the delivery of scaffold 100 to implant location ILOC.
  • Scaffold 100 can be configured to be removed after at least 1 day, 1 week, and/or 1 month of the delivery of scaffold 100 to implant location ILOC.
  • scaffold 100 comprises at least one self-expanding portion.
  • scaffold 100 comprises a weave construction. In some embodiments, scaffold 100 comprises a lattice construction.
  • scaffold 100 comprises a varying diameter along its length.
  • scaffold 100 is configured to be delivered to an implant location ILOC that is proximate a damaged area of hollow structure HS.
  • the damaged area can comprise an area of perforated tissue.
  • the perforated tissue can comprise perforated tissue of a bowel.
  • system 10 can be configured to prevent further injury and/or to promote healing.
  • System 10 can be configured to promote healing via ingrowth of tissue adjacent the implant location.
  • System 10 can further comprise delivery device 200 as shown, and delivery device 200 can be configured to deliver scaffold 100 to implant location ILOC.
  • delivery device 200 comprises a radially expandable element, expandable element 250 shown (e.g., a balloon, a mesh net, a mallicot, an expandable cage, and/or an unfurlable element), which can be configured to expand and apply a force to scaffold 100 (e.g., when scaffold 100 is implanted) and/or to another component of system 10.
  • expandable element 250 can be configured to expand and apply a force to tissue of the patient, such as force applied to location ILOC of hollow structure HS (during and/or after delivery of scaffold 100 to location ILOC).
  • delivery device 200 comprises a percutaneous delivery device, such as a catheter configured to be percutaneously introduced into a patient.
  • delivery device 200 comprises a surgical delivery device and/or a laparoscopic delivery device.
  • delivery device 200 comprises an endoscope.
  • system 10 further comprises dilation assembly 300, which can include a radially expandable element, expandable element 350, each as shown. Similar to expandable element 250 of delivery device 200, expandable element 350 can be configured to expand and apply a force to scaffold 100 (e.g., when scaffold 100 is implanted) and/or to another component of system 10. Alternatively or additionally, expandable element 350 can be configured to expand and apply a force to tissue of the patient, such as force applied to location ILOC of hollow structure HS (during and/or after delivery of scaffold 100 to location ILOC). Force applied to tissue by dilation assembly 300 at or otherwise proximate implant location ILOC can be applied prior to, during, and/or after implantation of scaffold 100 at location ILOC. In some embodiments, delivery device 200 comprises dilation assembly 300 (e.g., expandable elements 250 and 350 are the same component).
  • Dilation assembly 300 can comprise a balloon catheter. Dilation assembly 300 can be configured to perform a low-pressure dilation. Dilation assembly 300 (e.g., expandable element 350) can comprise an energy delivery element, a sonic disruption element, a lithotripsy element, and/or a cutting element.
  • Dilation assembly 300 e.g., expandable element 350
  • Dilation assembly 300 can comprise an energy delivery element, a sonic disruption element, a lithotripsy element, and/or a cutting element.
  • system 10 further comprises console 500, as shown.
  • Console 500 can comprise a device which operatively connects to delivery device 200 and/or one or more other components of system 10.
  • Console 500 can comprise a controller, controller 510 shown.
  • Controller 510 can comprise one or more electronic elements, electronic assemblies, and/or other electronic components, such as components selected from the group consisting of: memory storage components; analog-to-digital converters; rectification circuitry; state machines; microprocessors; microcontrollers; filters and other signal conditioners; sensor interface circuitry; transducer interface circuitry; and combinations thereof.
  • controller 510 comprises a memory storage component, memory 515, which can be coupled to other components of controller 510.
  • Memory 515 can store or otherwise include instructions, such as instructions used by controller 510 to perform one or more algorithms, algorithm 550 shown.
  • Algorithm 550 can comprise a machine learning algorithm, a neural network, and/or other artificial intelligence algorithm (“Al algorithm” herein).
  • algorithm 550 is configured to produce a procedural parameter related to a procedure of the present inventive concepts (e.g., a medical procedure performed using system 10).
  • system 10 further comprises one or more accessory devices, accessory device 600 shown.
  • Accessory device 600 can comprise one or more devices that are configured to score tissue (e.g., score vessel wall tissue), scoring device 610 shown.
  • Accessory device 600 can comprise one or more devices configured to expand, stretch, deform, and/or otherwise modify a lumen of the patient, lumen altering device 620 shown.
  • Lumen altering device 620 can comprise an angioplasty balloon, a cutting balloon, a cryoplasty balloon, an atherectomy device, and/or a device configured to treat a vascular calcification.
  • Accessory device 600 can comprise one or more devices configured to perform a lithotripsy procedure, lithotripsy device 630 shown.
  • Lumen altering device 620 can comprise device 630 (e.g., lumen altering device 620 can comprise a lithotripsy device).
  • Accessory device 600 can comprise one or more devices configured to occlude a space within a patient, space occluding device 640 shown. Each accessory device 600 can comprise one or more devices configured to access an internal location of a patient percutaneously. Each accessory device 600 can comprise one or more devices configured to be advanced through an endoscope, a laparoscopic port, and/or a vascular introducer.
  • Scoring device 610 can be configured to score hollow structure HS prior to, during, and/or after the delivery of scaffold 100 to the implant location ILOC.
  • Scoring device 610 can comprise a device selected from the group consisting of scoring sheath; cutting sheath; cutting balloon; and combinations thereof.
  • Scoring device 610 can be configured to treat the hollow structure HS if the hollow structure HS comprises a lumen with a stenosis of at least 7mm, and/or if hollow structure HS comprises a stenosis of at least 50% (e.g., when compared to normal vessel or viscus).
  • Lumen altering device 620 can comprise a device configured to increase and/or decrease the cross sectional area of a lumen of hollow structure HS.
  • Hollow structure HS can be a hollow body organ.
  • Lumen altering device 620 can comprise a surgical device and/or laparoscopic device.
  • Lumen altering device 620 can comprise a dilation device, such as a balloon catheter device.
  • Lithotripsy device 630 can comprise a lithotripsy device configured to disrupt and/or destroy tissue and/or other material within hollow structure HS.
  • the lithotripsy device can be configured to perform the disruption and/or destruction of tissue (e.g., tissue at or proximate implant location ILOC) prior to the delivery of scaffold 100.
  • Space occluding device 640 can comprise a device configured to reduce space within at least one portion of hollow structure HS.
  • Space occluding device 640 can comprise one, two, or more space occluding elements, such as occlusive coils, occlusive agents (e.g., fluids), and/or covered stents.
  • Space occluding device 640 can comprise a delivery device, such as a delivery device configured to deliver one or more space occluding elements of device 640.
  • hollow structure HS can comprise an aneurysm, and space occluding device 640 can be configured to deliver one or more occlusive elements.
  • space occluding device 640 is configured to modify the flow of fluid through hollow structure HS (e.g., via delivery of occlusive elements that partially or fully occlude a lumen of hollow structure HS). The modification of flow can comprise a reduction in flow.
  • hollow structure HS can comprise a TIPS shunt that is modified by device 640.
  • Hollow structure HS can comprise an arteriovenous fistula, and space occluding device 640 can be configured to stop flow through the arteriovenous fistula (e.g., via the delivery of a covered stent and/or occlusive agents in or proximate the fistula).
  • Hollow structure HS can comprise a portion of the GI tract, and space occluding device 640 can be configured to reduce flow through the portion of the GI tract, such as to treat dumping syndrome.
  • Space occluding device 640 can comprise one or more occlusive elements that can be configured to bioabsorb over time.
  • Space occluding device 640 can be configured to modify flow through hollow structure HS for a limited period of time (e.g., by the delivery of one or more occlusive elements that bioabsorb over a time period).
  • the one or more occlusive elements of device 640 can be configured to be effectively bioabsorbed within a time period, such as a time period of no more than: 1 hour, 8 hours, 1 day, 1 week, 1 month, 3 months, 6 months, and/or 1 year.
  • the one or more space occluding elements of device 640 can be configured to remain effectively in place for a time period, such as a time period of at least: 1 hour, 8 hours, 1 day, 1 week, 1 month, 3 months, 6 months, and/or 1 year (e.g., after which scaffold 100 can be configured to be effectively bioabsorbed).
  • System 10 can comprise one or more functional elements, such as functional element 99, functional element 199 of scaffold 100, functional element 299 of delivery device 200, functional element 399 of dilation assembly 300, functional element 599 of console 500, and/or functional element 699 of accessory device 600, each as shown in Fig.
  • Functional elements 99, 199, 299, 399, 599, and/or 699 can comprise one, two, or more sensors, one, two or more transducers, and/or one, two, or more other functional elements.
  • Functional element 199 can comprise a sensor, such as an implantable sensor.
  • the sensor can be configured to produce a signal
  • system 10 can be configured to produce data based on the sensor signal.
  • System 10 can be configured to analyze the data to determine a system parameter (e.g., a scaffold 100 parameter and/or a treatment parameter).
  • Scaffold 100 can comprise the sensor (e.g., functional element 199 comprises the sensor).
  • System 10 can be configured to treat hollow structure HS in a percutaneous procedure, in a minimally invasive procedure, in an open surgical procedure, and/or in a procedure including a combination of two or more of these clinical techniques.
  • the treatment is performed without image guidance.
  • image guidance can be used (e.g., as described herein).
  • System 10 can be configured to treat a hollow structure HS in a clinical procedure in which the hollow structure HS is prepared or otherwise treated (e.g., as described herein) prior to the implantation of scaffold 100.
  • This treatment performed prior to implantation of scaffold 100 can comprise a treatment procedure selected from the group consisting of expansion of tissue; constraining of tissue; perforation of tissue (e.g., for anchoring of scaffold 100 and/or absorption of agent 150 or other agent); and combinations of these.
  • System 10 can be configured to treat a blood vessel (e.g., a vein, an artery, or both) and/or other hollow structure HS, where the treatment comprises an initial treatment (e.g., a treatment using lumen altering device 620 or otherwise) and a secondary treatment that includes implantation of scaffold 100, as described herein.
  • the first treatment and the second treatment can be performed in the same clinical procedure.
  • the first treatment can be performed in a first clinical procedure
  • the second treatment can be performed in a second clinical procedure, such as a second clinical procedure that is performed at least 1 day, 1 week, or 1 month after the first clinical procedure.
  • the first treatment procedure can comprise use of lumen altering device 620, such as when device 620 is configured to perform: balloon angioplasty; balloon angioplasty in which the balloon is inflated beyond a nominal pressure, such as when inflated to at least 110% of nominal pressure; balloon angioplasty that is performed multiple times at a single anatomical location; balloon angioplasty in which the balloon is maintained expanded for a period of at least 5 minutes; atherectomy including multiple passes of the atherectomy element through the same anatomical location; and combinations of these.
  • the second treatment procedure comprises implantation of scaffold 100 (e.g., a scaffold configured to bioabsorb over time, and/or be removed after a pre-determined implantation duration, as described herein).
  • scaffold 100 is implanted only if the outcome of the first treatment is below a desired result, such as a desired result of residual stenosis being less than 30% (e.g., when determined using IVUS, angiography or other imaging technology).
  • System 10 can be configured to treat a hollow structure HS via a first treatment procedure in which the hollow structure is treated with lumen altering device 620 or other component of system 10, and a second treatment procedure, performed after the first treatment procedure, in which scaffold 100 is implanted.
  • the system 10 components used in the first treatment procedure are configured to cause hollow structure HS to accurately “match” the scaffold 100 (e.g., accurately match the dimensions of scaffold 100, such as to create a void or an imprint into which scaffold 100 is positioned).
  • the system 10 components used in the first treatment procedure deposit an agent (e.g., agent 150) and/or a structure (e.g., a functional element 99) into, through, and/or on the wall of the hollow structure HS.
  • the agent and/or structure can be configured as a guide, an anchor, and/or a “lock and key” mechanism for scaffold 100.
  • a functional element 199 (e.g., of scaffold 100) and/or a functional element 99 comprises a component that is implanted at the implant location, and is configured to deliver one or more of radiation; an agent (e.g., an agent 150 comprising a chemotherapeutic agent; a contrast agent; and/or a bio-active agent).
  • Method 1000 of Fig. 1 A can comprise a medical procedure in which scaffold 100 is implanted using one or more other products of system 10.
  • a patient is selected for treatment using the systems and methods of the present inventive concepts.
  • the patient has received a medical procedure in which an undesired condition has resulted, and method 1000 is performed to improve that undesired condition.
  • an “implantation step” is performed.
  • the implantation procedure includes implanting scaffold 100 at an implant location ILOC of a hollow structure HS of the patient.
  • delivery device 200 is used for the implantation of scaffold 100.
  • an optional “diagnostic step” can be performed, such as a procedure in which the efficacy (e.g., current or predicted future efficacy) of the implantation of scaffold 100 at implant location ILOC is assessed.
  • an optional “scaffold modification step” can be performed, such as a procedure in which scaffold 100 is expanded, contracted, moved, and/or otherwise modified.
  • Method 1000 can comprise additional procedures, such as one, two, or more treatment and/or diagnostic procedures (e.g., pharmaceutical treatment procedures, surgical procedures, interventional procedures, physical therapy procedures, and/or other medical procedures).
  • treatment and/or diagnostic procedures e.g., pharmaceutical treatment procedures, surgical procedures, interventional procedures, physical therapy procedures, and/or other medical procedures.
  • system 10 is configured (e.g., scaffold 100 and/or one or more other components of system 10 are configured) to provide a temporary scaffolding force to a hollow structure HS at the implant location ILOC.
  • hollow structure HS treated using system 10 comprises a blood vessel.
  • the blood vessel can comprise a vein and/or an artery.
  • the blood vessel can comprise a blood vessel that has been previously treated, at a previous treatment location, such as a previous treatment location that can be at and/or at least proximate the implant location ILOC of scaffold 100.
  • the previous treatment can comprise a treatment selected from the group consisting of treatment with a cutting balloon; treatment with a cutting sheath; treatment with an atherectomy device; treatment with a lithotripsy device; treatment that achieves a lumen improvement; treatment that does not achieve a lumen improvement; treatment of a vascular calcification; and/or combinations thereof.
  • hollow structure HS can comprise an artery or a vein
  • system 10 can be configured to provide a temporary scaffolding force to a luminal wall portion of the artery or vein.
  • the implant location ILOC can comprise a segment of a vein including one or more venous valves.
  • the one or more venous valves can comprise valves that have been previously disrupted and/or otherwise previously treated.
  • the implant location ILOC can comprise a vein segment that is in one or more of the following conditions: spasm; torn; disrupted; perforated; and/or damaged.
  • System 10 can be configured to reduce the likelihood of a stricture forming at or otherwise proximate the implant location ILOC.
  • the stricture can comprise a stricture that might occur due to a subsequent clinical procedure (e.g., wherein the procedure performed using system 10 is performed as a preventative measure to potentially prevent or at least reduce the future stricture formation).
  • the subsequent clinical procedure can comprise a procedure that is to be performed at or proximate the implant location ILOC.
  • system 10 is configured (e.g., scaffold 100 and/or one or more other components of system 10 are configured) to provide at least temporary incompetence of one or more venous valves located at the implant location ILOC.
  • the one or more venous valves can comprise at least one venous valve that has been previously disrupted and/or otherwise treated (e.g., in a previous clinical procedure performed just prior, or at least 1 day prior to the system 10 procedure).
  • System 10 can be configured to provide chronic incompetence of one of the one or more venous valves located at the implant location.
  • the chronic incompetence can comprise incompetence of the one or more venous valves for at least 1 month, 3 months, and/or 6 months.
  • hollow structure HS treated using system 10 comprises a hollow body organ.
  • the hollow body organ can be treated at a location proximate to the implant location ILOC of scaffold 100.
  • Scaffold 100 can be configured to provide a scaffolding force for a limited time period (e.g., limited due to the bioabsorption of scaffold 100).
  • the scaffolding force provided by scaffold 100, and/or scaffold 100 itself can be configured to support and/or promote healing of the hollow body organ (e.g., at or otherwise proximate the implant location ILOC).
  • the hollow body organ can comprise a tear duct, an eustachian tube, and/or a fallopian tube.
  • the hollow body organ can comprise a biliary structure.
  • the biliary structure can comprise an intra and/or extrahepatic duct structure.
  • the hollow body organ can comprise a urinary structure.
  • the urinary structure can comprise the ureter, urethra, and/or intra prostatic urethra.
  • the hollow body organ can comprise a gastrointestinal structure.
  • the gastrointestinal structure can comprise the esophagus, stomach, small intestine, large intestine, and/or colon.
  • the hollow body organ can comprise a structure of the pulmonary system, such as the bronchus.
  • hollow structure HS treated using system 10 comprises an aneurysm.
  • Scaffold 100 can be configured for placement across a neck of the aneurysm.
  • scaffold 100 can be configured to bioabsorb over a time period.
  • System 10 can further comprise an embolic coil, an embolic fluid, and/or other embolic component configured to be placed within the aneurysm.
  • hollow structure HS treated using system 10 comprises a diseased and/or damaged hollow structure.
  • the diseased and/or damaged hollow structure HS can comprise a focal tissue issue.
  • the focal tissue issue can comprise a bum, ischemia, laceration, tissue disruption, and/or tumor.
  • the diseased and/or damaged hollow structure HS can comprise a perforation of the hollow structure HS.
  • the diseased and/or damaged hollow structure HS can comprise at least a partial transection of hollow structure HS.
  • the at least a partial transection can comprise a full transection.
  • hollow structure HS treated using system 10 comprises a tubular structure, and scaffold 100 is configured to allow remodeling and/or healing of the tubular structure at and/or otherwise proximate the implant location ILOC.
  • the scaffold can be configured to bioabsorb over time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medical Informatics (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Prostheses (AREA)

Abstract

L'invention concerne des systèmes pour réaliser un acte médical. Le système peut comprendre un échafaudage destiné à être implanté dans une structure creuse d'un patient mammifère. L'invention concerne également des méthodes pour réaliser un acte médical.
PCT/US2024/030709 2023-05-23 2024-05-23 Système de traitement d'un patient Pending WO2024243381A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363503729P 2023-05-23 2023-05-23
US63/503,729 2023-05-23

Publications (2)

Publication Number Publication Date
WO2024243381A2 true WO2024243381A2 (fr) 2024-11-28
WO2024243381A3 WO2024243381A3 (fr) 2025-02-13

Family

ID=93590389

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/030709 Pending WO2024243381A2 (fr) 2023-05-23 2024-05-23 Système de traitement d'un patient

Country Status (1)

Country Link
WO (1) WO2024243381A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663308B2 (en) * 2005-09-19 2014-03-04 Cook Medical Technologies Llc Graft with bioabsorbable support frame
US20100042206A1 (en) * 2008-03-04 2010-02-18 Icon Medical Corp. Bioabsorbable coatings for medical devices

Also Published As

Publication number Publication date
WO2024243381A3 (fr) 2025-02-13

Similar Documents

Publication Publication Date Title
KR102845618B1 (ko) 양성 전립선 비대증 및 관련 하부 요로 증상의 치료를 위한 디바이스
US7232432B2 (en) Particle-removing medical device and method
US20150151077A1 (en) Devices And Methods For Renal Denervation
US20050251246A1 (en) Dilating and support apparatus with disease inhibitors and methods for use
JP2002065862A (ja) 溝付脈管ステント装置及び方法
US6932091B2 (en) Method for surgically restoring coronary blood vessels
US10575972B2 (en) Medical device with induction triggered anchors and system for deployment of the same
Jackson et al. A viewpoint on material and design considerations for oesophageal stents with extended lifetime
CN103974676A (zh) 利用生物可吸收支架的内膜下重通
Bettocchi et al. Penile prostheses
US20070021840A1 (en) Temporal stricture expander
Kurzer et al. Endoscopic management of ureterointestinal strictures after radical cystectomy
AU2010366132A1 (en) Removable stent and method of production
Petruzziello et al. Stenting in esophageal strictures
WO2024243381A2 (fr) Système de traitement d'un patient
US20230011734A1 (en) Devices and systems for improving stent performance
US20100234934A1 (en) Balloon Deployable Coronary Stent
Herr et al. Ureteral interventions
Geavlete et al. Urethral stents
WO2014036809A1 (fr) Dispositifs d'administration de médicament endoluminaux ayant des applications dans des vaisseaux sanguins
Viswanathan et al. Balloons and Stents
Amato et al. Evolution of surgical techniques for a progressive risk reduction
Jha Sustainable Heat Integrated Encapsulation Long Lasting Delivery (SHIELD): Revolutionizing Stent-Based Therapy with On-Demand, Personalized Drug Release
CN117942206A (zh) 一种可回收给药系统及其应用
WO2025188864A1 (fr) Traitement de rétrécissement sans cathéter à demeure